<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Urology reports (St. - Petersburg)</journal-id><journal-title-group><journal-title xml:lang="en">Urology reports (St. - Petersburg)</journal-title><trans-title-group xml:lang="ru"><trans-title>Урологические ведомости</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Urology reports (St. - Petersburg)</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2225-9074</issn><issn publication-format="electronic">2687-1416</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">691525</article-id><article-id pub-id-type="doi">10.17816/uroved691525</article-id><article-id pub-id-type="edn">NEGSDX</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Impact of hypertension on lower urinary tract symptoms in men with benign prostatic hyperplasia</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние артериальной гипертензии на симптомы нижних мочевыводящих путей у мужчин с доброкачественной гиперплазией предстательной железы</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9584-756X</contrib-id><contrib-id contrib-id-type="spin">4064-2757</contrib-id><name-alternatives><name xml:lang="en"><surname>Krupin</surname><given-names>Aleksei V.</given-names></name><name xml:lang="ru"><surname>Крупин</surname><given-names>Алексей Валентинович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>av.krupin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4887-4888</contrib-id><contrib-id contrib-id-type="spin">8892-7661</contrib-id><name-alternatives><name xml:lang="en"><surname>Krupin</surname><given-names>Valentin N.</given-names></name><name xml:lang="ru"><surname>Крупин</surname><given-names>Валентин Николаевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>vn.krupin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5120-2620</contrib-id><contrib-id contrib-id-type="spin">5508-5724</contrib-id><name-alternatives><name xml:lang="en"><surname>Sevryukov</surname><given-names>Fedor A.</given-names></name><name xml:lang="ru"><surname>Севрюков</surname><given-names>Федор Анатольевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>fedor_sevryukov@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6350-8165</contrib-id><name-alternatives><name xml:lang="en"><surname>Makarov</surname><given-names>Oleg E.</given-names></name><name xml:lang="ru"><surname>Макаров</surname><given-names>Олег Евгеньевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>lioton@yandex.ru</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1138-1174</contrib-id><contrib-id contrib-id-type="spin">5753-4302</contrib-id><name-alternatives><name xml:lang="en"><surname>Nashivochnikova</surname><given-names>Natalya A.</given-names></name><name xml:lang="ru"><surname>Нашивочникова</surname><given-names>Наталья Алексеевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>dom17.doctor@mail.ru</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0503-6128</contrib-id><contrib-id contrib-id-type="spin">1998-7812</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuyarov</surname><given-names>Anton S.</given-names></name><name xml:lang="ru"><surname>Куяров</surname><given-names>Антон Сергеевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>kuyarov.anton@mail.ru</email><xref ref-type="aff" rid="aff5"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6195-9758</contrib-id><name-alternatives><name xml:lang="en"><surname>Ulitin</surname><given-names>Igor B.</given-names></name><name xml:lang="ru"><surname>Улитин</surname><given-names>Игорь Борисович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. биол. наук, доцент</p></bio><email>ulitin_ib@mail.ru</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Privolzhsky Research Medical University</institution></aff><aff><institution xml:lang="ru">Приволжский исследовательский медицинский университет</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Clinical Hospital “Russian Railways-Medicine”</institution></aff><aff><institution xml:lang="ru">Клиническая больница «РЖД-Медицина»</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">L.A. Vorokhobov City Clinical Hospital No. 67</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница № 67 им. Л.А. Ворохобова</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Clinical Hospital “Russian Railways-Medicine”</institution></aff><aff><institution xml:lang="ru">Клиническая больница «РЖД-Медицина»</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Privolzhsky Research Medical University</institution></aff><aff><institution xml:lang="ru">Приволжский исследовательский медицинский университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-12-22" publication-format="electronic"><day>22</day><month>12</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-12-30" publication-format="electronic"><day>30</day><month>12</month><year>2025</year></pub-date><volume>15</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>371</fpage><lpage>378</lpage><history><date date-type="received" iso-8601-date="2025-10-06"><day>06</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-12-22"><day>22</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-01-27"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/uroved/article/view/691525">https://journals.eco-vector.com/uroved/article/view/691525</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:<italic> </italic></bold>Impaired blood supply to the bladder is considered a risk factor for urinary dysfunction, including in patients with benign prostatic hyperplasia. One of the possible causes of pelvic hemodynamic disturbances is hypertension.</p> <p><bold>AIM<italic>:</italic></bold> This study aimed to evaluate the impact of hypertension on the severity of lower urinary tract symptoms in patients with benign prostatic hyperplasia.</p> <p><bold>METHODS:</bold> This retrospective and prospective observational study included 6117 men aged 48 to 83 years (mean age: 59.57 ± 10.1 years) who underwent surgical treatment for benign prostatic hyperplasia; 5960 patients were included in the final analysis. Medical records were reviewed with assessment of International Prostate Symptom Score, ultrasonographic findings of the prostate and bladder, and the presence and characteristics of comorbid conditions.</p> <p><bold>RESULTS:</bold> Hypertension was identified in 3052 (51.2%) patients, of whom only 1385 (45.4%) were aware of the diagnosis. Patients with benign prostatic hyperplasia and concomitant hypertension demonstrated greater severity of lower urinary tract symptoms, with significant differences observed not only in overall International Prostate Symptom Score but also separately for storage and voiding symptoms. The severity of urinary dysfunction, primarily storage symptoms, depended on the stage and duration of hypertension, as well as on pharmacological blood pressure control. The presence of hypertension influenced the likelihood of persistent urinary dysfunction after surgical treatment of benign prostatic hyperplasia. In the postoperative period, lower urinary tract symptoms were observed in 2078 (68.1%) of 3052 patients with hypertension, compared with only 577 (19.8%) of 2908 patients without hypertension.</p> <p><bold>CONCLUSION:</bold> Hypertension is associated with increased severity of lower urinary tract symptoms in patients with benign prostatic hyperplasia; the duration and stage of hypertension, as well as antihypertensive therapy, are of significance. Hypertension may be considered a risk factor for persistent lower urinary tract symptoms in the long-term postoperative period. Prior to deciding on surgical intervention for benign prostatic hyperplasia in patients with hypertension, adequate blood pressure control followed by reassessment of lower urinary tract symptom severity appears to be necessary.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.<italic> </italic></bold>Нарушение кровоснабжения мочевого пузыря рассматривают как фактор риска развития расстройств мочеиспускания, в том числе у больных доброкачественной гиперплазией предстательной железы. Одна из возможных причин гемодинамических расстройств в органах малого таза — гипертоническая болезнь.</p> <p><bold>Цель исследования.</bold> Оценить влияние артериальной гипертензии на выраженность симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы.</p> <p><bold>Методы.</bold> В ретро- и проспективном наблюдательном исследовании объектом исследования было 6117 мужчин в возрасте 48–83 лет (средний возраст 59,57±10,1 года), оперированных по поводу доброкачественной гиперплазии предстательной железы, из которых 5960 были включены в окончательный анализ. Был проведен анализ историй болезни, при котором учитывали результаты анкетирования по опроснику IPSS, ультразвукового исследования простаты и мочевого пузыря, а также наличие и характер сопутствующих заболеваний.</p> <p><bold>Результаты.</bold> Гипертоническая болезнь была выявлена у 3052 (51,2%) пациентов, при этом только 1385 (45,4%) из них знали о ее наличии. У больных доброкачественной гиперплазией предстательной железы с сопутствующей гипертонической болезнью была бóльшая выраженность симптомов нижних мочевыводящих путей, при этом статистически значимое различие отмечено не только для общей суммы баллов IPSS, но и отдельно для симптомов накопления и симптомов опорожнения. Выраженность расстройств мочеиспускания, в первую очередь симптомов накопления, зависела от стадии гипертонической болезни, ее длительности, а также от медикаментозной коррекции артериального давления. Наличие гипертонической болезни влияло на вероятность сохранения нарушений мочеиспускания после оперативного лечения доброкачественной гиперплазии предстательной железы. Из 3052 пациентов с артериальной гипертензией в послеоперационном периоде симптомы нижних мочевыводящих путей отмечены у 2078 (68,1%) пациентов, в то время как из 2908 пациентов без гипертонической болезни — только у 577 (19,8%).</p> <p><bold>Заключение.</bold> Артериальная гипертензия ассоциирована с большей выраженностью симптомов нижних мочевыводящих путей у больных доброкачественной гиперплазией предстательной железы, при этом имеет значение длительность и стадия гипертонической болезни, а также проведение гипотензивной терапии. Наличие артериальной гипертензии можно рассматривать как фактор риска сохранения симптомов нижних мочевыводящих путей в отдаленные сроки после операции. Перед принятием решения о хирургическом вмешательстве по поводу доброкачественной гиперплазии предстательной железы у пациентов с гипертонической болезнью представляется необходимым проведение адекватной гипотензивной терапии с последующей повторной оценкой выраженности симптомов нижних мочевыводящих путей.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>prostate hyperplasia</kwd><kwd>benign prostatic hyperplasia</kwd><kwd>lower urinary tract symptoms</kwd><kwd>hypertension</kwd><kwd>high blood pressure</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гиперплазия предстательной железы</kwd><kwd>доброкачественная гиперплазия предстательной железы</kwd><kwd>симптомы нижних мочевыводящих путей</kwd><kwd>гипертоническая болезнь</kwd><kwd>артериальная гипертензия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Azadzoi KM, Chen BG, Radisavljevic ZM, et al. Molecular reactions and ultrastructural damage in the chronically ischemic bladder. J Urol. 2011;186(5):2115–2122. doi: 10.1016/j.juro.2011.06.047</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mudraya IS, Ibragimov AR, Kirpatovsky VI, et al. Functional assessment of rat urinary bladder with Fourier impedance cystometry. Experimental and Clinical Urology. 2010;(3):21–26. EDN: OPFARN</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kirpatovsky VI, Sivkov AV, Fedyakov RP, et al. Role of blood supply disturbance and tissue hypoxia in the development of bladder dysfunction in bladder outlet obstruction caused by the prostatic adenoma. Urologiia. 2013;(2):132–138. EDN: QAWDCB</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kirpatovsky VI, Mudraya IS, Mkrtchyan KG, et al. Ischemia in pelvic organs as an independent pathogenic factor in the development of benign prostatic hyperplasia and urinary bladder dysfunction. Bulletin of Experimental Biology and Medicine. 2014;158(12):676–680. doi:10.1007/s10517-015-2845-5 EDN: TCABQB</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015;22(1):40–46. doi: 10.1111/iju.12652</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol Urodyn. 2014;33(1):54–58. doi: 10.1002/nau.22517</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8): F738–F743. doi: 10.1152/ajprenal.00333.2015</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kushakovsky MS. Essential hypertension (hypertensive disease). Causes, mechanisms, clinical features, treatment. 5th ed. Saint Petersburg: Foliant; 2002. 414 p. ISBN: 5-93929-045-0 EDN: ZWAKCF</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Safaryan AS, Sargsyan VD. Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part I. Cardiovascular Therapy and Prevention. 2020;19(6):2693. doi: 10.15829/1728-8800-2020-2693 EDN: YMWLYP</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Andersson KE, Nomiya M, Sawada N, et al. Pharmacological treatment of chronic pelvic ischemia. Therapeutic Advances in Urology. 2014;6(3): 105–114. doi: 10.1177/1756287214526768 EDN: SPJGAB</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hwang EC, Kim SO, Nam DH, et al. Men with hypertension are more likely to have severe lower urinary tract symptoms and large prostate volume. LUTS: Low Urin Tract Symptoms. 2015;7(1):32–36. doi: 10.1111/luts.12046</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kapoor H, Gupta E, Sood A. Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management. Minerva Urol Nefrol. 2014;66(2):127–137.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chen IH, Tsai YS, Tong YC. Correlations among cardiovascular risk factors, prostate blood flow, and prostate volume in patients with clinical benign prostatic hyperplasia. Urology. 2012;79(2):409–414. doi: 10.1016/j.urology.2011.09.039</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Shimizu S. Insights into the associative role of hypertension and angiotensin II receptor in lower urinary tract dysfunction. Hypertens Res. 2024;47(4):987–997. doi: 10.1038/s41440-024-01597-8 EDN: OECMCK</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sugaya K, Kadekawa K, Ikehara A, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol. 2003;10(11):569–754. doi: 10.1046/j.1442-2042.2003.00707.x EDN: EUBNCR</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Onigbinde SO, Asaleye CM, Salako AA, et al. The effect of systemic hypertension on prostatic artery resistive indices in patients with benign prostate enlargement. Prostate Int. 2023;11(1):46–50. doi: 10.1016/j.prnil.2022.09.001 EDN: ADVIZI</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Gacci M, Corona G, Sebastianelli A, et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis. Eur Urol. 2016;70(5):788–796. doi: 10.1016/j.eururo.2016.07.007</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Güven EO, Selvi I, Karaismailoğlu E. Association between benign prostate enlargement-related storage and voiding symptoms and systolic blood pressure: a single-center cross-sectional study. Sao Paulo Med J. 2019;137(5):446–453. doi: 10.1590/1516-3180.2018.0543.R3.160919</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Luo F, Sun HH, Su YH, et al. Assessment of noninvasive predictors of bladder detrusor underactivity in BPH/LUTs patients. Int Urol Nephrol. 2017;49(5):787–792. doi: 10.1007/s11255-017-1539-5 EDN: YYJRAF</mixed-citation></ref></ref-list></back></article>
